IBIO insider Form 4: CFO awarded 75,000 options, vesting over 3 years
Rhea-AI Filing Summary
iBio (IBIO) reported an insider equity grant: its Chief Financial Officer received 75,000 stock options at an exercise price of $0.893 on 10/20/2025. The options are exercisable starting 10/20/2026 and expire on 10/19/2035.
Vesting is 25% on the one-year anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over 36 months, contingent on continued employment. Following the grant, the officer beneficially owned 75,000 derivative securities, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Duran Felipe
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 75,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 75,000 shares (Direct)
Footnotes (1)
- F1. These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did IBIO disclose in this Form 4?
The CFO received 75,000 stock options at an exercise price of $0.893, granted on 10/20/2025.
What is the vesting schedule for the IBIO CFO’s options?
Vesting is 25% on the first anniversary, then equal quarterly installments over 36 months, subject to continued employment.
When can the IBIO CFO begin exercising these options?
The options become exercisable starting on 10/20/2026.
When do the IBIO CFO’s options expire?
The options expire on 10/19/2035.
How many derivative securities does the IBIO CFO own after the grant?
Following the reported transaction, the officer beneficially owned 75,000 derivative securities.
What was the price paid for the option grant?
The grant price for the derivative security was $0; the exercise price is $0.893 per share.